Merck To Present New Data Across Its HIV Treatment And Prevention Pipeline And Portfolio At HIV Drug Therapy Glasgow 2026

Presentations include data on daily and investigational once-weekly oral treatments and investigational once-monthly oral HIV pre-exposure prophylaxis

New data include Phase 3 subgroup analyses and patient-reported outcomes of investigational once-weekly oral combination of islatravir/lenacapavir (ISL/LEN)

Merck (NYSE:MRK), known as MSD outside of the United States and Canada, announced todaythat new data across its HIV treatment and prevention pipeline and portfolio will be presented at HIV Drug Therapy Glasgow 2026 (HIV Glasgow 2026), taking place Nov 8–11, 2026, in Glasgow, Scotland. Presentations will highlight Merck’s strategy to expand oral options in both HIV treatment and prevention, including data on once-daily IDVYNSO® (doravirine/islatravir), the investigational once-weekly oral treatment regimens islatravir/lenacapavir (ISL/LEN) and islatravir/ulonivirine (ISL/ULO), and the investigational once-monthly oral pre-exposure prophylaxis (PrEP) alimatravir (AMI, MK-8527).